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Coronaviruses are single-stranded, positive 
ribonucleic acid viruses, belonging to the family 
Coronaviridae that can cause disease in birds, 
mammals and humans.1 In December 2019, the city of 
Wuhan, China, became the center of a viral outbreak 
that attracted great international attention. The 
causative agent of the disease was isolated, and it was 
determined to be a new coronavirus in January 2020. 
Following SARS-CoV (2002) and MERS-CoV (2012), 
this is the third coronavirus outbreak reported in the 
current century.2  
 
This novel coronavirus 2019 has rapidly spread from 
China to almost every corner of the globe. Due to this 
illness, around eight lac people were infected and 
more than 38000 died worldwide by 1st April 2020 with 
United States being the country with the highest 
number of victims. It has been observed that the virus 
most frequently affects older adults, 
immunocompromised people or people with 
comorbidities.2  
 
In this review we offer a panoramic view of the current 
knowledge related to the treatment and therapeutic 
alternatives for COVID-19, from drugs that have been 
regularly used in other diseases with proven antiviral 
activity, to drugs that have usually been used as 
antiparasitic or antibacterial but that, in the current 
situation, are again known for their possible and 





Preventive administration of antibiotics should not be 
performed without microbiologically confirming 
bacterial superinfection.4 There are not yet any 
licensed vaccines or therapeutic agents to treat 
coronavirus infection, highlighting the urgent need to 
develop effective vaccines or post-exposure 
prophylaxis to prevent future epidemics. COVID-19 
resembles SARS-CoV infection in a few genetic, 
clinical and epidemiological characteristics. Therefore, 
advances in research on the treatment of this virus 
could help develop effective therapeutic agents.1 
 
ARBIDOL (UMIFENOVIR) 
Umifenovir has been shown to have a direct antiviral 
effect on early viral replication of SARS-CoV in vitro.5 
Arbidol inhibits virus-mediated fusion with the target 
membrane, thereby blocking viral entry into the target 
cells.6 This product is used as a treatment for influenza 
in Russia and China and has been claimed to be 
effective in the therapy of COVID-19 in a 
concentration range of 10-30 μM, in vitro. A 
multicenter randomized controlled trial with arbidol 
has been initiated in China in patients with COVID-
19.7 As per the results of a study, this drug showed a 
trend to improve patient discharge rate and reduce 
mortality in a small cohort of patients with COVID-19.6 
 
REMDESIVIR  
Remdesivir is a prophylactic analogue of adenosine 
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vitro.8 
  
 It has been recognized as an antiviral agent with a 
promising potential against a wide range of RNA virus 
infections in animal/in-vitro studies. Furthermore, it is 
in stage of clinical development for the treatment of 
Ebola virus infection.9 It was used to treat the first 
COVID-19 patient in USA and resulted in a reduced 
viral load in nasopharyngeal and oropharyngeal 
samples, and the patient's clinical condition 
improved.10,11 Phase III clinical trials have also been 
conducted for evaluating the use of intravenous 
remdesivir in patients with COVID -19.12 
 
LOPINAVIR/ RITONAVIR 
The protease inhibitors lopinavir and ritonavir, used in 
treating HIV infection, could improve the condition of 
patients with SARS and MERS viral infection.8 The 
systematic review by Yao et al. reports that most in 
vitro studies have shown that lopinavir can inhibit 
SARS-CoV. In addition, two cohort studies of SARS-
CoV patients revealed that lopinavir/ritonavir plays a 
critical role in clinical outcome, especially in the early 
stage. Treatment with lopinavir/ritonavir improved 
clinical outcomes in some patients with MERS-CoV 
and this could be an effective treatment against 
COVID-19 based on the previous experience against 
SARS and MERS.13 In an adult patient with COVID-19 
in Korea, the viral load significantly decreased after the 
administration of lopinavir/ritonavir.14 
 
As per a published protocol for the restricted use of 
this association in symptomatic patients during a 
public health emergency, adult patients hospitalized 
by COVID-19 were eligible to receive this combination 
drug for 14 days after signing the informed consent and 
if useful, further evaluation by a randomized control 




This drug underwent clinical trials for evaluation of 
efficacy and safety in the treatment of COVID-19 with 
promising results.16 Favipiravir is a new type of RNA 
polymerase inhibitor17 that becomes an active 
phosphoribosylating form in cells and is recognized as 
a substrate by viral RNA polymerase, thus inhibiting 
the activity of RNA polymerase.18 The preliminary 
result of a clinical trial indicated that favipiravir had a 
more potent antiviral action than lopinavir/ritonavir. 
No   significant   drug   related   safety    signals   were  
 
observed in the favipiravir treatment group which had 
significantly lower adverse reactions than the 
lopinavir/ritonavir group. Therefore, the favipiravir 
would have a possible antiviral action in COVID-19.16 
 
TEICOPLANIN 
The knowledge-based hit and trial of existing drugs 
can be a quick and effective way in identifying drugs 
with a known safety profile in treating an emerging 
disease. Teicoplanin, a glycopeptide used to treat 
gram-positive bacterial infections has been found to be 
active, in vitro, against SARS-CoV. It has joined the list 
of molecules that could be used as therapeutic arsenal 
in COVID-19 as it has demonstrated its efficacy against 
several viruses such as HIV, Ebola, flavivirus, influenza 
virus, hepatitis C virus, SARSCoV and MERS-CoV(19). 
This drug prevents the viral RNA release and 
interrupts the replication cycle of corona virus, so is 




Chloroquine, an effective anti- malarial drug has been 
used for many years and has a great potential in 
treating COVID-19 infection. It can inhibit the pH-
dependent steps of replication of various viruses with 
a potent effect on the infection and spread of SARS-
CoV. In addition, this drug has immune-modulatory 
effects, which suppress the production and release of 
TNF-α and IL-6. Research publications have reported 
that this drug interferes with the glycosylation process 
of SARS-CoV cell receptors and also works in the entry 
and post-entry stages of infection in Vero E6 cells. 
When combined with remdesivir, has also been shown 
to effectively inhibit the virus in-vitro.8 As per recent 
studies, it may improve the clinical outcome of 
patients infected with SARS-CoV-2. It is also assumed 
that chloroquine also interferes with the glycation of 
the ACE2 receptor, thus preventing the binding of the 
virus to target cells.22  
 
As reported by Wang et al, the expression of RCT2 is 
increased by SARS coronavirus in lung tissue, and this 
may accelerate its replication as well as spread.23 It also 
alters virion assembly and germination by interfering 
with proteolytic processing of M-protein and it could 
act indirectly by haltering the production of pro-
inflammatory cytokines and activating antiviral CD8+ 
T cells.24 
 
It   is    reported   that there  is  preclinical  evidence of  
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efficacy-safety for long-term clinical use in other 
diseases that justify clinical investigation of 
chloroquine use in patients with COVID-19.24 
 
HYDROXYCHLOROQUINE 
Hydroxychloroquine and chloroquine are active 
against malaria and have similar pharmacokinetics but 
differ in their toxic doses and by the presence of a 
hydroxyl group. The advantage of hydroxychloroquine 
is that it can be used in high doses for long periods 
with very good tolerance.22,25 Both drugs have 
equivalent antiviral activity, but hydroxychloroquine 
has a better safety profile than chloroquine. In patients 
with COVID-19, these drugs may interact with 
lopinavir/ritonavir or azithromycin, resulting in 
prolongation of the QT interval. Other therapeutic 
agents for COVID-19 are currently being investigated, 
such as antivirals (oseltamivir, lopinavir/ritonavir or 
ribavirin), interferons and intravenous 
immunoglobulins that do not interfere with 
hydroxychloroquine.26 
 
Zhou et al. propose that hydroxychloroquine, which 
shows an antiviral effect very similar to that of 
chloroquine, could serve as a better therapeutic 
approach. Hydroxychloroquine is likely to suppress T-
cell activation, leading to inhibition of the cytokine 
storm and ultimately hinder the severe progression of 
COVID-19. In addition, it has a better safety profile and 
may be administered in pregnant patients.27 
 
AZITHROMYCIN 
The antibiotic azithromycin has also gained attention 
during this deadly outbreak. A non-randomized, open-
label clinical trial was conducted to evaluate the role 
of azithromycin along with hydroxychloroquine in 
respiratory viral loads. Subjects with COVID-19 were 
included in the study and received study drugs and 
their viral loads were analyzed in nasopharyngeal 
swabs. Untreated patients from another center and 
cases who did not accept the protocol were included 
in the study as negative controls. The treated subjects 
showed a significant reduction in viral load compared 
to controls on 6th day after inclusion. Azithromycin 
added to hydroxychloroquine was significantly more 
effective in combatting the virus. The study showed 
that the combination treatment was significantly 
associated with viral load reduction/disappearance in 
patients with COVID-19.28 This combination stands 
efficacious, but azithromycin is known to potentiate 




COVID-19 virus outbreak has handicapped the 
medical, financial and public health infrastructure 
across the globe. Current actions are focused on social 
distancing, hand sanitization, disinfection of 
surroundings and quarantine of infected subjects. An 
effective and safe vaccine against this pandemic might 
be the ultimate answer, but until such a remedy is 
available it is important to focus also on 
pharmacological therapies of interest such as 
described in this piece of literature. In depth research 
on the pathogenesis of COVID-19 might help in 
discovery of appropriate targets for development of 
specific agents against this global enemy. Healthcare 
researchers are working hard and significant progress 
in identifying therapeutic alternatives to drugs has 
been made, controlled studies are required to find out 
in detail the efficacy as well as safety profile of drugs 
that stand as potential candidates for the treatment of 
subjects with COVID-19 infection. Meanwhile, it is 
important to follow therapeutic regimens 
recommended by health authorities at individual, 
national and global levels. 
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